海思科：创新药HSK47977片获得FDA药物临床试验批准

Core Viewpoint - The company has received FDA approval to proceed with clinical trials for its self-developed oral BCL6PROTAC small molecule drug, HSK47977, aimed at treating lymphoma [1] Group 1 - The FDA issued a Study May Proceed Letter to the company, allowing the clinical trial for HSK47977 to commence [1] - HSK47977 has also received clinical trial approval from the National Medical Products Administration (NMPA) in August [1] - The company has successfully enrolled the first subject for the clinical trial [1]